​

Charles River Laboratories (CRL) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChartTranscripts

CRL Stock Forecast

Charles River Laboratories (CRL) stock forecast, based on 37 Wall Street analysts, predicts a 12-month average price target of $214.14, with a high of $220.00 and a low of $192.00. This represents a 0.67% increase from the last price of $212.71.

$175 $195 $215 $235 $255 $275 High: $220 Avg: $214.14 Low: $192 Last Closed Price: $212.71

CRL Stock Rating

Charles River Laboratories stock's rating consensus is Buy, based on 37 Wall Street analysts. The breakdown includes 1 Strong Buy (2.70%), 26 Buy (70.27%), 10 Hold (27.03%), 0 Sell (0.00%), and 0 Strong Sell (0.00%).

Buy
Total 37 10 26 1 Strong Sell Sell Hold Buy Strong Buy

CRL Price Target Upside V Benchmarks

TypeNameUpside
StockCharles River Laboratories0.67%
SectorHealthcare Stocks 15.45%
IndustryDiagnostics & Research Stocks11.63%

Price Target Trends

1M3M12M
# Anlaysts2823
Avg Price Target$219.50$213.63$207.43
Last Closing Price$212.71$212.71$212.71
Upside/Downside3.19%0.43%-2.48%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Jun, 263103-117
May, 262104-117
Apr, 261106--17
Mar, 261107--18
Feb, 261107--18
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Jun 17, 2026Morgan Stanley$220.00$184.7919.05%3.43%
May 29, 2026CLSA$219.00$181.3420.77%2.96%
May 08, 2026Eric ColdwellRobert W. Baird$213.00$175.5621.33%0.14%
May 08, 2026Evercore ISI$220.00$176.3224.77%3.43%
May 08, 2026Mizuho Securities$192.00$181.685.68%-9.74%
May 08, 2026Luke SergottBarclays$220.00$181.6821.09%3.43%
Apr 14, 2026Luke SergottBarclays$210.00$178.3417.75%-1.27%
Apr 14, 2026RBC Capital$215.00$178.3420.56%1.08%
Feb 20, 2026Mizuho Securities$175.00$164.246.55%-17.73%
Feb 19, 2026Eric ColdwellRobert W. Baird$193.00$158.1822.01%-9.27%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Jun 17, 2026Morgan StanleyOverweightupgrade
May 29, 2026CLSAUnderperformOutperformupgrade
May 08, 2026Evercore ISIOutperformOutperformhold
May 08, 2026BarclaysOverweightOverweighthold
Apr 14, 2026BarclaysOverweightOverweighthold
Apr 14, 2026RBC CapitalOutperforminitialise
Apr 08, 2026Evercore ISIOutperformOutperformhold
Feb 20, 2026Cowen & Co.BuyBuyhold
Feb 19, 2026BarclaysOverweightOverweighthold
Jan 22, 2026Cowen & Co.BuyBuyhold

Financial Forecast

EPS Forecast

$-5 $0 $5 $10 $15 $20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$7.77$9.57$9.27$0.20$-2.91---
Avg Forecast$10.26$10.89$10.59$10.19$9.88$11.00$12.43$14.23
High Forecast$10.51$11.15$10.68$10.30$12.56$12.63$15.07$15.26
Low Forecast$9.96$10.70$10.45$10.12$9.10$9.71$10.39$13.52
Surprise %-24.27%-12.12%-12.46%-98.04%-129.45%---

Revenue Forecast

$3B $3B $4B $4B $5B $5B Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$3.54B$3.98B$4.13B$4.05B$4.02B---
Avg Forecast$3.52B$3.91B$4.11B$4.03B$3.93B$4.16B$4.37B$4.63B
High Forecast$3.59B$3.98B$4.12B$4.05B$4.07B$4.18B$4.42B$4.89B
Low Forecast$3.44B$3.86B$4.10B$4.02B$3.77B$4.15B$4.31B$4.46B
Surprise %0.50%1.64%0.55%0.47%2.23%---

Net Income Forecast

$-150M $40M $230M $420M $610M $800M Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$390.98M$486.23M$474.62M$10.30M$-144.34M---
Avg Forecast$364.08M$454.69M$474.62M$525.43M$557.17M$574.85M$654.91M$732.15M
High Forecast$436.89M$545.62M$569.55M$530.07M$646.04M$650.02M$775.34M$785.01M
Low Forecast$291.26M$363.75M$379.70M$520.79M$468.30M$499.69M$534.47M$695.76M
Surprise %7.39%6.94%--98.04%-125.91%---

CRL Forecast FAQ

Is Charles River Laboratories stock a buy?

Charles River Laboratories stock has a consensus rating of Buy, based on 37 Wall Street analysts. The rating breakdown includes 1 Strong Buy, 26 Buy, 10 Hold, 0 Sell, and 0 Strong Sell, reflecting a consensus that Charles River Laboratories is a favorable investment for most analysts.

What is Charles River Laboratories's price target?

Charles River Laboratories's price target, set by 37 Wall Street analysts, averages $214.14 over the next 12 months. The price target range spans from $192 at the low end to $220 at the high end, suggesting a potential 0.67% change from the previous closing price of $212.71.

How does Charles River Laboratories stock forecast compare to its benchmarks?

Charles River Laboratories's stock forecast shows a 0.67% upside, underperforming the average forecast for the healthcare stocks sector (15.45%) and underperforming the diagnostics & research stocks industry (11.63%).

What is the breakdown of analyst ratings for Charles River Laboratories over the past three months?

  • June 2026: 17.65% Strong Buy, 58.82% Buy, 17.65% Hold, 0% Sell, 5.88% Strong Sell.
  • May 2026: 11.76% Strong Buy, 58.82% Buy, 23.53% Hold, 0% Sell, 5.88% Strong Sell.
  • April 2026: 5.88% Strong Buy, 58.82% Buy, 35.29% Hold, 0% Sell, 0% Strong Sell.

What is Charles River Laboratories’s EPS forecast?

Charles River Laboratories's average annual EPS forecast for its fiscal year ending in December 2026 is $11, marking a -478.01% decrease from the reported $-2.91 in 2025. Estimates for the following years are $12.43 in 2027, and $14.23 in 2028.

What is Charles River Laboratories’s revenue forecast?

Charles River Laboratories's average annual revenue forecast for its fiscal year ending in December 2026 is $4.16B, reflecting a 3.68% increase from the reported $4.02B in 2025. The forecast for 2027 is $4.37B, and $4.63B for 2028.

What is Charles River Laboratories’s net income forecast?

Charles River Laboratories's net income forecast for the fiscal year ending in December 2026 stands at $574.85M, representing a -498.27% decrease from the reported $-144M in 2025. Projections indicate $654.91M in 2027, and $732.15M in 2028.